Acupuncture Reduces Frequency of Chronic Tension-Type Headaches
Responder rate higher with true acupuncture (needling to achieve deqi sensation) versus superficial acupuncture (sham control)
Migraine and Headache
Neurological Symptoms Persist After SARS-CoV-2 Infection
Memory impairment and decreased concentration most prevalent symptoms at six-month follow-up
Atogepant Prevents Migraine in Adults
Compared with placebo, increase in responder rates seen at all atogepant dose levels
Lidocaine Infusions Beneficial for Refractory Chronic Migraine
Decrease seen in median pain rating from baseline to end of hospitalization; pain rating remained below baseline at postdischarge visit
FDA to Review Intranasal Zavegepant for Migraine Treatment
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
COVID-19 Drug Paxlovid Might Also Fight Long COVID
Series of case reports shows some success with Paxlovid in treating patients with long COVID
FDA Delays Decision on Meloxicam/Rizatriptan Combo for Migraine
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Review: Transcranial Direct Current Stimulation Eases Migraine
Active stimulation with tDCS can reduce the number of migraine days per month, pain intensity
Labeling for Migraine Treatment Rimegepant Updated With Lactation Data
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Atogepant Reduces Monthly Migraine Days in Chronic Migraine Trial
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.
